Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Octreotide in Aggressive Recurrent Meningiomas
NCT02333565Phase 2Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2015
- Primary completion
- Jan 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, octreotide in meningioma, sponsored by Assistance Publique-Hôpitaux de Marseille. Started Jan 2015; status: completed.
02
Drugs
everolimusoctreotide
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT02333565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333565.